November 29, 2014 5:06 AM ET

Company Overview of The Global Alliance for TB Drug Development

Executive Profile

Melvin K. Spigelman M.D.

Chief Executive Officer, President and Director, The Global Alliance for TB Drug Development
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 3 different industries.

See Board Relationships
65--

Background

Dr. Melvin K. Spigelman, also known as Mel, M.D. is the Chief Executive Officer and President of Global Alliance for TB Drug Development. Dr. Spigelman has been at Global Alliance for TB Drug Development since January 2009 and also serves as a Director. Dr. SpHe igelman served as a Research and Development Director since 2003 at the firm. He serves as a Venture Partner at Wellington Partners Venture Capital GmbH since joining the firm in May 2005 and focuses on the life ...

Corporate Headquarters

--
--, -- --

United States

Phone: --
Fax: --

Board Members Memberships

Chief Executive Officer, President and Director
2005-Present
Independent Director and Member of Nominating & Corporate Governance Committee
2008-Present
Director, Chairman of External Communication Oversight Committee, Member of Compensation Committee and Member of Audit Committee

Education

BA
Brown University
MD
Mount Sinai School Of Medicine

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Global Alliance for TB Drug Development, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.